Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Leishmania major | serine-threonine protein kinase-like protein | 0.0002 | 0 | 0.5 |
Trypanosoma brucei | Forkhead Kinase, putative | 0.0002 | 0 | 0.5 |
Schistosoma mansoni | serine/threonine protein kinase | 0.0724 | 1 | 1 |
Trypanosoma cruzi | STE/STE11 serine/threonine-protein kinase, putative | 0.0002 | 0 | 0.5 |
Leishmania major | protein kinase, putative | 0.0002 | 0 | 0.5 |
Echinococcus granulosus | MAP kinase activated protein kinase 2 | 0.0724 | 1 | 1 |
Leishmania major | protein kinase, putative | 0.0002 | 0 | 0.5 |
Echinococcus multilocularis | MAP kinase activated protein kinase 2 | 0.0724 | 1 | 1 |
Trypanosoma cruzi | STE/STE11 serine/threonine-protein kinase, putative | 0.0002 | 0 | 0.5 |
Trypanosoma cruzi | STE/STE11 serine/threonine-protein kinase, putative | 0.0002 | 0 | 0.5 |
Entamoeba histolytica | protein kinase, putative | 0.0043 | 0.0561 | 1 |
Loa Loa (eye worm) | camk/mapkapk/mapkapk protein kinase | 0.0724 | 1 | 0.5 |
Entamoeba histolytica | protein kinase, putative | 0.0043 | 0.0561 | 1 |
Leishmania major | protein kinase, putative | 0.0002 | 0 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Activity (functional) | = 0.15 % dose (g of tissue)-1 | Distribution (percent dose/g of tissue) of radioactivity 24 hr after intravenous administration of [125I]-labeled compound in rat heart | ChEMBL. | 7097714 |
Activity (functional) | = 0.21 % dose (g of tissue)-1 | Distribution (percent dose/g of tissue) of radioactivity 24 hr after intravenous administration of [125I]-labeled compound in rat blood | ChEMBL. | 7097714 |
Activity (functional) | = 0.29 % dose (g of tissue)-1 | Distribution (percent dose/g of tissue) of radioactivity 24 hr after intravenous administration of [125I]-labeled compound in rat plasma | ChEMBL. | 7097714 |
Activity (functional) | = 0.43 % dose (g of tissue)-1 | Distribution (percent dose/g of tissue) of radioactivity 24 hr after intravenous administration of [125I]-labeled compound in rat lung | ChEMBL. | 7097714 |
Activity (functional) | = 1.31 % dose (g of tissue)-1 | Distribution (percent dose/g of tissue) of radioactivity 24 hr after intravenous administration of [125I]-labeled compound in rat spleen | ChEMBL. | 7097714 |
Activity (functional) | = 3.99 % dose (g of tissue)-1 | Distribution (percent dose/g of tissue) of radioactivity 24 hr after intravenous administration of [125I]-labeled compound in rat liver | ChEMBL. | 7097714 |
Activity (functional) | = 5.97 % dose (g of tissue)-1 | Distribution (percent dose/g of tissue) of radioactivity 24 hr after intravenous administration of [125I]-labeled compound in rat ovary | ChEMBL. | 7097714 |
Activity (functional) | = 9.19 % dose (g of tissue)-1 | Distribution (percent dose/g of tissue) of radioactivity 24 hr after intravenous administration of [125I]-labeled compound in rat adrenal cortex | ChEMBL. | 7097714 |
Activity (functional) | = 46.31 % dose (g of tissue)-1 | Distribution(percent dose/g of tissue) of radioactivity 24 hr after intravenous administration of [125I]-labeled compound in rat thyroid | ChEMBL. | 7097714 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.